Protein C News and Research

RSS

Study finds second skin barrier structure may play a role in eczema development

Like a fence or barricade intended to stop unwanted intruders, the skin serves as a barrier protecting the body from the hundreds of allergens, irritants, pollutants and microbes people come in contact with every day.

20 Dec 2010

Nanosphere's Verisens cTnI assay measures low levels of troponin I in patients with heart failure

A clinical study released online by the European Journal of Heart Failure, a publication of the European Society of Cardiology, demonstrates the value of using Nanosphere's Verisens cTnI assay to detect very low levels of troponin I in hospitalized patients with heart failure.

20 Dec 2010

23andMe project aims at validating highly scalable pharmacogenomics research

23andMe has launched a project funded by the National Institutes of Health which is aimed at validating 23andMe's highly-scalable platform for pharmacogenomics research. The company received $190,000 in stimulus funding from the American Recovery and Reinvestment Act of 2009 for "Web-based Phenotyping for Genome-Wide Association Studies of Drug Response" from NIH's National Human Genome Research Institute.

17 Dec 2010

Researchers discover new way to prevent spread of cancer

Scientists now know that some cancer cells spread, or metastasize, throughout the body the old-fashioned way -- by using their feet. But researchers at Duke Cancer Institute have discovered a way to short-circuit their travels by preventing the development of these feet, called invadopodia. This discovery is even more important because preventing the development of these "feet" also eliminates the action of proteins present in the feet that burn through intact tissue and let cancer cells enter new cells.

17 Dec 2010

BioMimetic granted Canadian notice of patent allowance covering rhPDGF-BB platform technology formulations

BioMimetic Therapeutics, Inc. announced today the Canadian Intellectual Property Office (CIPO) has allowed patent application No. 2,583,823 titled "Platelet Derived Growth Factor (PDGF) Compositions and Methods of Use Thereof". The new patent will remain in force until October 2025, during which time it will prohibit the marketing of similar or generic versions of the Company's Augment™ orthopedic product line and certain other rhPDGF-BB product formulations.

17 Dec 2010

Gene variant affects brain function long before brain begins accumulating amyloid: Study

People with a known, high risk for Alzheimer's disease develop abnormal brain function even before the appearance of telltale amyloid plaques that are characteristic of the disease, according to a new study.

17 Dec 2010

'Histone code' needs to be used with caution

The function of histones -- the proteins that enable yards of DNA to be crammed into a single cell -- depends on a number of chemical tags adorning their exterior. This sophisticated chemical syntax for packaging DNA into tight little coils or unraveling it again -- called the "histone code" -- is the latest frontier for researchers bent on understanding how genetics encodes life.

17 Dec 2010

Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients

Viron Therapeutics Inc. today announced that the results of Viron's Phase 2a trial for VT-111 were published today in Circulation: Cardiovascular Interventions. In the study led by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, VT-111, also known as Serp-1, met both its primary and secondary endpoints of safety and biological activity in Acute Coronary Syndrome patients receiving coronary stents.

17 Dec 2010

Prions responsible for BSE can survive in new host environment

Scientists from the Florida campus of The Scripps Research Institute have shown that prions, bits of infectious protein that can cause fatal neurodegenerative disease such as bovine spongiform encephalopathy or "mad cow disease," have the ability to adapt to survive in a new host environment.

17 Dec 2010

Study suggests blood test may detect persons with CKD

An infrequently used blood test can effectively identify individuals at increased risk of developing complications associated with chronic kidney disease (CKD), according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

17 Dec 2010

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

The Muscular Dystrophy Association today announced it has awarded $1.4 million in new research funding to the biopharmaceutical firm Repligen of Waltham, Mass., to complete the preclinical work needed to begin human clinical trials of a promising therapeutic compound for spinal muscular atrophy (SMA).

17 Dec 2010

Researchers discover new molecular mechanism of Alzheimer's disease through protein interaction

Through a complex analysis of protein interactions, researchers from IRB Barcelona and the Joint Programme IRB-BSC have discovered new molecular mechanisms that may be involved in the development of Alzheimer's disease.

17 Dec 2010

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, presented new data at the 2010 International Chemical Congress of Pacific Basin Societies, being held in Honolulu, Hawaii, December 15-20.

17 Dec 2010

Genetic biomarker linked to increased risk for breast cancer found in 'junk' DNA

A new genetic biomarker that indicates an increased risk for developing breast cancer can be found in an individual's "junk" (non-coding) DNA, according to a new study featuring work from researchers at the Virginia Bioinformatics Institute (VBI) at Virginia Tech and their colleagues.

17 Dec 2010

AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development

With a grant of USD 475,000, the Michael J. Fox Foundation is funding preclinical development of a vaccine against Parkinson's disease by AFFiRiS AG. The vaccine, known as PD01, targets the protein alpha-synuclein and might offer for the first time a possibility for a treatment that can slow or stop the progression of Parkinson's disease.

17 Dec 2010

Study: Biomarkers may aid in early diagnosis of breast cancer

Using a new, powerful method for rapidly screening molecules associated with disease, proteomics expert Joshua LaBaer and colleagues from the Biodesign Institute at Arizona State University have identified a broad panel of 28 early predictors, or biomarkers, that may one day aid in the early diagnosis of breast cancer.

17 Dec 2010

Scientists decipher genetic code for pediatric medulloblastoma

Scientists at the Johns Hopkins Kimmel Cancer Center have deciphered the genetic code for medulloblastoma, the most common pediatric brain cancer and a leading killer of children with cancer.

16 Dec 2010

FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate

Novavax, Inc. announced today that the company's Phase I clinical trial to evaluate a new vaccine candidate to prevent respiratory syncytial virus (RSV) infection has been cleared by the U.S. Food and Drug Administration (FDA) and is no longer on clinical hold. In November, the company reported that it had received a question from the FDA regarding chemistry, manufacturing and controls (CMC) that has now been resolved.

16 Dec 2010

Study describes CC3/TIP30 protein regulate metabolic adaptation of tumor cells to glucose limitation

Bionovo, today announced the publication of a study entitled "CC3/TIP30 regulates metabolic adaptation of tumor cells to glucose limitation" in the journal Cell Cycle.

16 Dec 2010

Zenobia, Lundbeck enter research collaboration for LRRK2 Parkinson's disease target

Zenobia Therapeutics, Inc. the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.

16 Dec 2010

Protein C News and Research

Study finds second skin barrier structure may play a role in eczema development

Nanosphere's Verisens cTnI assay measures low levels of troponin I in patients with heart failure

23andMe project aims at validating highly scalable pharmacogenomics research

Researchers discover new way to prevent spread of cancer

BioMimetic granted Canadian notice of patent allowance covering rhPDGF-BB platform technology formulations

Gene variant affects brain function long before brain begins accumulating amyloid: Study

'Histone code' needs to be used with caution

Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients

Prions responsible for BSE can survive in new host environment

Study suggests blood test may detect persons with CKD

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

Researchers discover new molecular mechanism of Alzheimer's disease through protein interaction

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

Genetic biomarker linked to increased risk for breast cancer found in 'junk' DNA

AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development

Study: Biomarkers may aid in early diagnosis of breast cancer

Scientists decipher genetic code for pediatric medulloblastoma

FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate

Study describes CC3/TIP30 protein regulate metabolic adaptation of tumor cells to glucose limitation

Zenobia, Lundbeck enter research collaboration for LRRK2 Parkinson's disease target

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News